Home Tags Remdesivir
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
So far, randomized controlled trials of remdesivir have been evaluating its safety and efficacy in hospitalized patients.
Whatever the supply may be, there may not be enough for everyone who may need it."
The median time to recovery was 11 days for patients treated with the drug compared with 15 days for those who received the placebo.
Gilead is also seeking to treat the virus earlier.
Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with COVID-19 and requiring supplemental oxygen therapy, according to the authors.
“We now have solid data showing that remdesivir diminishes to a modest degree the time to recovery for people hospitalized with COVID-19,” said NIAID Director Anthony S. Fauci, M.D.
«You will only observe with your eyes and see the punishment of the wicked. If you say, “The Lord is my refuge”, and you...